Scandion Oncology has announced the appointment of Francois Martelet, MD, as CEO, effective from 2 January 2023, when he will take over from acting CEO and CFO Johnny Stilou. Francois brings more than 30 years of pharmaceutical industry experience to Scandion, and will lead the development of Scandion’s chemotherapy sensitising drug SCO-101 in colorectal and pancreatic cancer. Previously, Francois held a number of biotech CEO positions and has extensive leadership experience at large pharmaceuti ....
01 Dec 2022
Scandion Oncology - Francois Martelet appointed as CEO
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Scandion Oncology - Francois Martelet appointed as CEO
- Published:
01 Dec 2022 -
Author:
Soo Romanoff -
Pages:
2
Scandion Oncology has announced the appointment of Francois Martelet, MD, as CEO, effective from 2 January 2023, when he will take over from acting CEO and CFO Johnny Stilou. Francois brings more than 30 years of pharmaceutical industry experience to Scandion, and will lead the development of Scandion’s chemotherapy sensitising drug SCO-101 in colorectal and pancreatic cancer. Previously, Francois held a number of biotech CEO positions and has extensive leadership experience at large pharmaceuti ....